Fertility considerations and preservation in haemato-oncology patients undergoing treatment.
about
Clinical guide to fertility preservation in hematopoietic cell transplant recipientsOocyte cryostorage to preserve fertility in oncological patients.Improving access to information and support for patients with less common cancers: hematologic cancer patients' views about Web-based approaches.Fertility preservation in girls.Fertility considerations in young women with hematological malignancies.Fertility in female survivors of Hodgkin's lymphoma.On-line information and support for supporters and carers of haematological cancer patients: is access an issue?Current approach to fertility preservation by embryo cryopreservationFertility-preserving treatment options in patients with malignant hematological diseases.Late endocrine effects of childhood cancer.Successful controlled ovarian stimulation and vitrification of oocytes in an adolescent diagnosed with myelodysplastic/pre-malignant clone with monosomy 7.Advances in fertility preservation of female patients with hematological malignancies.Fertility Management for the Hemato-Oncologist.Ovarian insufficiency and pubertal development after hematopoietic stem cell transplantation in childhood.Possible therapeutic use of spermatogonial stem cells in the treatment of male infertility: a brief overview.Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.Candidate SNP markers of reproductive potential are predicted by a significant change in the affinity of TATA-binding protein for human gene promoters.
P2860
Q33809651-9B52C8C5-7E00-4961-9FA4-A617864A4774Q35691780-5DACFA78-DDCC-4D34-A338-71F28BB60664Q35752729-F40913DD-AD15-4D2D-8A50-E3E379FF5341Q35838156-A8D9802F-A7B4-4E95-ACAD-4C0CF48AF95AQ36016181-5B20F055-AB6C-4C07-ABDF-26AD6419CE59Q36283790-1DDB3E46-CEC2-4769-85D1-567B2E003A68Q36288168-5A0553AA-6F46-4F04-9C11-076D6FA5A573Q37676012-3415B563-D066-4933-B3F8-926815726E1BQ37702800-3FB04B98-89DD-4D74-8B60-423FFBFC5FECQ38794942-DD2C5C9B-DA38-4F1A-8419-2F7E2EC4EE21Q39418670-F8D3C229-3081-4D2E-868B-1CC1B859E86FQ47662579-03E63A85-51B8-42C4-9DB7-EC928229F6B3Q48109711-F2636B59-5191-42FA-B7E9-6DE03E842336Q51121663-C12467BE-9052-4F1E-A2A9-B8800B9F6697Q51606011-BA6B7557-F03A-4C96-815B-3A9E11A59C4FQ53116636-61030DA9-CE12-43A5-82FA-00E4D1B1909FQ54936700-E522BE9D-8165-429E-9597-571CA1088077
P2860
Fertility considerations and preservation in haemato-oncology patients undergoing treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Fertility considerations and p ...... patients undergoing treatment.
@en
Fertility considerations and p ...... patients undergoing treatment.
@nl
type
label
Fertility considerations and p ...... patients undergoing treatment.
@en
Fertility considerations and p ...... patients undergoing treatment.
@nl
prefLabel
Fertility considerations and p ...... patients undergoing treatment.
@en
Fertility considerations and p ...... patients undergoing treatment.
@nl
P2860
P1476
Fertility considerations and p ...... patients undergoing treatment
@en
P2093
Avi Leader
Michael Lishner
P2860
P304
P356
10.1111/J.1365-2141.2011.08629.X
P407
P577
2011-03-09T00:00:00Z